Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: Hubert Road
Brentwood
Essex CM14 4JY
,United Kingdom
Tel: +44 (0) 1277 266 600
Web: http://www.martindalepharma.co.uk/
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century. The company’s reputation as a leading UK manufacturer and supplier of specialty prescription pharmaceutical products for healthcare professionals, working in both Primary and Secondary Care, has grown steadily over that time. Martindale Pharma is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets. Martindale Pharma has a clearly defined mission: to provide medicines to improve the quality of people’s lives.
Martindale Pharma has built strong relationships with prescribers and influencers on drug choice in its chosen business segments (see below). Working on the basis of a partnership, Martindale Pharma has also built a strong relationship with healthcare service providers such as Alliance Boots, Celesio, AAH, Lloyds, Co-Operative Pharmacies, as well as the NHS. Our operating philosophy is one of close co-operation and responsiveness to customer needs.
Key Business Segments:
Addiction
Martindale Pharma is ranked number one in market share in the opiate addiction market, driven by the success of our brand Physeptone, the UK’s leading methadone product. We work in partnership with the NHS, Community Drug Teams, third party providers of addiction services as well as retail pharmacies to ensure that drug service users receive the optimum support as they seek to move away from the use of illicit opiates.
Critical Care
Martindale Pharma manufacture and market the Aurum Range, the UK’s leading range of 11 pre-filled syringes for emergency use by resuscitation and operating theatre teams. We also manufacture and market a Caffeine product for treatment of Apnoea of Prematurity a critical care area in neonatology.
Specials
Martindale Pharma can manufacture over 30,000 products in a range of formulations. Handling around 700-800 individual orders a day for these highly personalised medicines, the majority of products are made by our dedicated team of pharmacists and technical staff. Over 90% of orders are supplied to the customer within 24 hours of ordering. Martindale Pharma is ranked number one by market share in this segment.
Ophthalmics
Martindale Pharma provides a broad range of ophthalmic products as generic, own label and third party brands. We are one of the top three companies in our chosen Ophthalmics disease segments.
Hospital Speciality Products
Martindale Pharma’s range of principally parenteral products are used in a wide range of hospital situations. We are one of the country’s leading manufacturers of sterile injection products supplying over 25 million ampoules a year.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee…
Originally published in the October 2025 edition of DIA’s Global Forum magazine, this article — authored by Mandy Budwal-Jagait, Kingyin Lee, Maria Urdaneta-Abate, Hedwig Ganguly, Rachel Mead, and Louisa Obillo…
As chief development officer of Moderna, Dr Melanie Ivarsson OBE spearheaded the rapid development of a COVID-19 vaccine that helped the world emerge from the pandemic. Now back in the…
Writing in the September 2025 edition of DIA’s Global Forum magazine, Janet Messer, Catherine Blewett, and Naho Yamazaki of the UK Health Research Authority (HRA) and Stephen Lam, Crina Cacou,…
Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France…
The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and…
Writing in the July 2025 edition of DIA Global Forum, Samantha Holmes, Fiona Adshead, and Keith Moore of the Sustainable Healthcare Coalition explore how cross-sector partnerships are advancing environmental sustainability…
Lenny Shallcross, Executive Director of the World Dementia Council, reflects on the evolving global response to Alzheimer’s disease and dementia; from the slow but significant rollout of disease-modifying treatments to…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
See our Cookie Privacy Policy Here